These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38644588)

  • 21. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.
    Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ
    Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Townsend CM; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
    Boyapati RK; Torres J; Palmela C; Parker CE; Silverberg OM; Upadhyaya SD; Nguyen TM; Colombel JF
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012540. PubMed ID: 29756637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
    Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA
    J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641
    [No Abstract]   [Full Text] [Related]  

  • 27. Serum Immune Profiling in Paediatric Crohn's Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments.
    Jongsma MME; Costes LMM; Tindemans I; Cozijnsen MA; Raatgreep RHC; van Pieterson M; Li Y; Escher JC; de Ridder L; Samsom JN
    J Crohns Colitis; 2023 Aug; 17(8):1262-1277. PubMed ID: 36934327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
    Syal G; Melmed GY; Almario CV; Spiegel BMR
    Dig Dis Sci; 2023 Feb; 68(2):404-413. PubMed ID: 36512266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China.
    Chen H; Shi J; Pan Y; Zhang Z; Fang H; Chen Y; Chen W; Cao Q
    Adv Ther; 2020 Jan; 37(1):431-449. PubMed ID: 31797196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
    Stevens TW; Haasnoot ML; D'Haens GR; Buskens CJ; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Mol B; Stokkers PCF; Bemelman WA; Ponsioen CY;
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):900-907. PubMed ID: 32619413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Tsoulis DJ; MacDonald JK
    Cochrane Database Syst Rev; 2013 Apr; (4):CD000545. PubMed ID: 23633304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab for maintenance of medically-induced remission in Crohn's disease.
    Gordon M; Sinopoulou V; Akobeng AK; Sarian A; Moran GW
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD012609. PubMed ID: 38372447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
    Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
    Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.
    Choi GK; Collins SD; Greer DP; Warren L; Dowson G; Clark T; Hamlin PJ; Ford AC
    J Crohns Colitis; 2014 May; 8(5):375-83. PubMed ID: 24129316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management for severe Crohn's disease: a lifetime cost-utility analysis.
    Jaisson-Hot I; Flourié B; Descos L; Colin C
    Int J Technol Assess Health Care; 2004; 20(3):274-9. PubMed ID: 15446756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
    Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L
    Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
    Gordon M; Taylor K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
    Schröder O; Blumenstein I; Stein J
    Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn's Disease Patients Treated With Combined Immunosuppressive Therapy.
    Kang B; Choi SY; Choi YO; Kim MJ; Kim K; Lee JH; Choe YH
    J Crohns Colitis; 2018 May; 12(6):644-652. PubMed ID: 29474531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
    Hanauer SB; Feagan BG; Lichtenstein GR; Mayer LF; Schreiber S; Colombel JF; Rachmilewitz D; Wolf DC; Olson A; Bao W; Rutgeerts P;
    Lancet; 2002 May; 359(9317):1541-9. PubMed ID: 12047962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.